Who
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $8.5M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Jan 2020
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,100 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,100 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —151,316 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,929 at $0.00 | filing |
| 9 Jun 2023filed 9 Jun 2023 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,205 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,091 at $0.00 | filing |
| 16 Dec 2021filed 17 Dec 2021 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,335 at $0.00 | filing |
| 2 Nov 2021filed 3 Nov 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $400K25,000 at $16.01 | filing |
| 1 Nov 2021filed 3 Nov 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $351K25,000 at $14.05 | filing |
| 26 Oct 2021filed 27 Oct 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $301K25,000 at $12.05 | filing |
| 25 Oct 2021filed 27 Oct 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $421K46,371 at $9.08 | filing |
| 21 Oct 2021filed 22 Oct 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $17K1,898 at $9.01 | filing |
| 20 Oct 2021filed 20 Oct 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $16K1,731 at $9.02 | filing |
| 18 Oct 2021filed 20 Oct 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $1.7M200,000 at $8.41 | filing |
| 30 Jul 2021filed 30 Jul 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $18K10,000 at $1.83 | filing |
| 30 Jul 2021filed 30 Jul 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $68K10,000 at $6.81 | filing |
| 30 Jul 2021filed 30 Jul 2021 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 25 Jun 2021filed 25 Jun 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $18K10,000 at $1.83 | filing |
| 25 Jun 2021filed 25 Jun 2021 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $81K10,000 at $8.13 | filing |
| 25 Jun 2021filed 25 Jun 2021 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
News
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaOCGN · manilatimes.net · 14 Oct 2026Ocugen (NASDAQ:OCGN) Stock: Insider Shankar Musunuri Sells 468,727 SharesOCGN · tickerreport.com · 14 Oct 2026Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?OCGN · prnewswire.com · 8 Oct 2026
0 headlines in the last 90 days name Uday Kompella; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.